Yixian Breast Tumor Hospital: Use more original research to change the efficacy of breast cancer patients

On September 11, 2020, the Yixian Breast Tumor Hospital officially announced its establishment in Guangzhou. The "Hospital of the Hospital", which was listed at the famous Sun Yixian Memorial Hospital of Sun Yat -sen University, immediately caused a widespread interest in the industry and society as "the first public breast and tumor hospital in China". In the past two years, the Yixian Breast Tumor Hospital is led by Professor Song Erwei, an academician of the Chinese Academy of Sciences and the dean of Sun Yaxian Memorial Hospital of Sun Yat -sen University. On the other hand, strengthening the comprehensive health management and complications of breast cancer patients is currently the most complete mammary tumor diagnosis and treatment complex of the domestic discipline team.

On the occasion of the "8.19" Physician's Day, the "Medical Daily" interviewed Professor Liu Qiang, Executive Deputy Dean of the Yixian Breast Tumor Hospital. Cancer therapy and diagnostic technology and unremitting efforts to Chinese breast and tumor cause.

Emerge

Do the "most comprehensive and most special" breast cancer hospital

"The establishment of the Yixian Breast Tumor Hospital is the increasingly increasing breast cancer disease and increasingly complicated and accurate breast cancer treatment technology." Liu Qiang said that when he was just engaged in surgery more than 20 years ago Many hospitals are just a small professional group. Compared with Europe and the United States, which is highly valued and developed with mature breast specialists, the development of Chinese breast college has always been not valued. Most of them are only a small branch of general surgery or thoracic surgery. It is also a single, mainly surgical resection.

However, statistics show that from 2000 to 2011, the incidence of breast cancer in China increased by 3.9%each year, the mortality rate increased by 1.1%, and the number of diseases of more than ten years increased. WHO data in 2020 shows that breast cancer is the first malignant tumor in the global women's incidence.

"Breast cancer is a wealthy disease." Professor Liu Qiang said that the per capita incidence of breast cancer in Europe and the United States is much higher than that of China. One of them will suffer from breast cancer at a certain time in this life, but This number in China is only 1/20-1/30. However, the mortality rate of breast cancer is obviously higher than Europe and the United States. The number of patients with breast cancer now 420,000, 120,000 deaths, and 28%of death, while only 16%in the United States, so the gap is still very large. On the other hand, the treatment of breast cancer is increasingly complicated and more advanced. Although many hospitals in my country have set up breasts or dairy nails in recent years, it is still difficult to match the incidence of breast cancer in my country and the increasingly complex breast cancer multidisciplinary diagnosis and treatment model. one of the reasons.

"It can be said that as long as it is a breast -related disease to come to us, there is basically nothing to solve, because our specialty is very complete," Liu Qiang said. Most patients' problems. Because of this, the Yixian Breast Tumor Hospital is based on 11 clinical Asian specialists and research institutions. It adopts a series of comprehensive treatment models such as surgery, chemotherapy, radiotherapy, endocrine therapy, targeted therapy, and even immunotherapy to provide full breast cancer patients. Integrity, one -stop integrated medical services, improve the sequence of patients' diagnosis and treatment, optimize the patient's diagnosis and treatment experience, escort the innovative comprehensive treatment model, and ensure the long -term quality of life of patients.

Precision treatment

Remove the sword of Damoris on the head of TNBC patient

Among the subtypes of breast cancer, although tri-negative breast cancer (TNBC) accounted for only 12%-17%of the overall breast cancer, it is a type of "most poisonous and fierce". A considerable part of the patients were resistant to the primary drug of chemotherapy drugs, which led to recurrence and metastasis soon. The survival period was the shortest after metastasis, which made many patients afraid of Sanyin breast cancer. Research data from Europe and the United States show that the median general survival (OS) of patients with recurrence and metastasis is only 14 months, which is far lower than the positive hormone receptor and HER2 positive patients for 40-60 months. So how to extend the lives of these patients as much as possible, scientists around the world have done a lot of research.

In Professor Liu Qiang's view, the combination of immunity and antemomhological drugs may be the best choice among many immune combination solutions. It is also one of the earliest reporters in the world that the immune combined antibodies generated for the treatment of three -negative breast cancer. Since 2017, the Yixian team carried out the research on immune combined antibodium production. In 2018, patients to formally admitted clinical research in the group were the world's first clinical research in antibroken generating joint immunotherapy. It was also the first time. Bold proposal: For chemotherapy for patients with Sanyin breast, only immunotherapy is performed.

"At that time, the breast cancer of Sanyin was mainly chemotherapy. Immunotherapy was very small all over the world at that time. Our research accident changed the fate of a considerable part of the patient."

One of the patients who were impressed by Liu Qiang spent millions of treatment in the United States, and the condition went to the whole body of the lungs, and the mentality of trying to participate in the experiment. moon;

Another 39 -year -old patient made him even more unforgettable: when the patient entered the clinic, the stench was smoked all over the other patients. He knew the situation that the patient's entire chest wall could be seen because the tumor was eroded, and the ribs and lungs could be seen. Bacteria infection caused a stench. The chemotherapy scheme was changed three or four times. She hugged the last line and hoped to contact the United States for treatment. As a result, she was informed by the American doctor: there is no good solution, so don't go. But this "chemotherapy" solution magically controlled her condition. "A few months later we had surgery for her, and she covered her chest wall wound with abdominal tissue. Now it has not made progress for more than 40 months. This patient returned from the outside not long ago. The quality of life is no different from ordinary people. This was an unimaginable effect before. "At present, the Yixian Breast Tumor Hospital has accumulated nearly 200 cases of immunization combined treatment. Among them, dozens of percent of patients have almost disappeared. At least 40 %. "Although it is regrettable, it is not effective for all patients with three -yin breast cancer, but it is a big step compared to before. We are also constantly studying, hoping to explore more updated methods and help these patients change to change changes. His fate, "Liu Qiang said.

Professor Liu Qiang's team reported in JCO precision oncology magazine the year before, reporting circulatory tumor DNA (CTDNA) to accurately predict the efficacy and recurrence risk of early breast cancer. After the article was published "one. Therefore, Liu Qiang's team carried out the first -centered multi -centered random control clinical study under the guidance of the first CTDNA guidance in the country, hoping to effectively relieve the fear and anxiety of TNBC patients for recurrence, and provide them with more accurate prognosis evaluation and upgrade treatment. Try to get the maximum possible cure opportunities in the early days.

Caring for young groups

Chinese women should be protected by Chinese

In December 2021, the first China Young Breast Cancer Summit Forum and Consensus Congress (YBCC) jointly launched by the Sun Yixian Memorial Hospital of Sun Yat -sen University Sun Yixian Memorial Hospital and the European Cancer Academy (ESO) were held in Guangzhou. Professor Olivia Pagani of ESO academic chairman said in a message that the treatment of young breast cancer is waiting for China to lead us and give us answers.

Behind this consensus and message is the characteristics of high incidence of young breast cancer unique to China.

Liu Qiang said that in China and even Southeast Asia, the median age of breast cancer is about 45 ~ 48 years old. However, in Europe and the United States, the age of the inhabitants is 62 ~ 64 years old, with a gap in a teenage. There are quite a few 20 or 30 -year -old breast cancer patients in China every year. He noticed a patient with a 21 -year -old breast cancer patient not long ago. There are more than 50,000 young breast cancer patients under 40 years of age in China, accounting for about 15%of the overall breast cancer people, which is much higher than Europe and the United States. Moreover, young breast cancer patients are a special group. In addition to the commonality of all patients with breast cancer, they also have their own unique characteristics. It requires longer survival and better quality of life. Special issues.

He mentioned a case. A 25 -year -old breast cancer patient, unmarried and unmarried. The local doctor only focused on cancer treatment, and did not give her extra fertility protection. "This case is a pity. In fact, the chance of that patient is completely cured is about 80%. She may have 5 or 60 years of life. She still wants to get married and have children. How can we maximize the ability and desire to protect her. It is very necessary. "

There is also a patient in his early 40s. Before he was sick, he was a beautiful woman with a very successful career. Because of the local chemotherapy plan, it caused greater side effects such as baldness and obesity. The image also crushes her heart. Now she stays at home and dares not to see people, and even starts to explain the funeral with her family, which makes her family very distressed. In Liu Qiang's view, it was just a case with a mild condition. "So for the treatment of young women, on the one hand, we want to be cured as much as possible, and on the other hand, we also hope to ensure that their shape is healthy and long -term quality of life. Like this woman, we can give her to use her? For the treatment of hair, I think she will definitely be different from now. "

Facing many clinical confusion about young breast cancer patients, Professor Liu Qiang took the lead in launching the first Chinese young breast cancer consensus compilation and discussion, and invited 137 experts from various interdisciplinary experts from breast surgery, internal medicine, radiotherapy, reproduction, and gynecology. Team voting. He said, "The purpose of our consensus is to guide clinical practice. We hope to reach the entire process of screening, diagnosis, surgery, radiotherapy, chemotherapy, endocrine therapy, and even follow -up process. Relatively consistent, at the same time, there is an overall guidance effect. "He emphasized," For the problem of Chinese characteristics, we must work hard to solve it by ourselves. "

Innovate the transformation of scientific research

Let the "Yixian model" affect the whole country

Under the leadership of Academician Song Erwei, the team of Yixian Breast Tumor Hospital is a model for training medical scientists. It is also a group of doctors scientists who are very closely combined with clinical and transformation research. Liu Qiang said, "The biggest advantage lies in the direction of clinical issues to guide scientific research, and scientific research results giving back clinical answers." The comprehensive team building and selfless academic heritage laid the international status of their theoretical research in the field of breast cancer. Models have obtained a number of original research from China, including the early fluid biopsy, which accurately identify high -risk people through liquid biopsy in Sanyin breast cancer, thereby changing the efficacy of patients with breast cancer patients.

As the executive vice president of the Yixian Breast Tumor Hospital, Liu Qiang is also thinking. As an emerging specialist in China, the treatment and diagnosis of breast tumors not only require a specialist, but also a team. The comprehensive treatment model is promoted to the whole country to benefit more patients?

Just two weeks ago, they signed a cooperation agreement with Xinjiang Oncology Hospital and the Affiliated Hospital of Guizhou Medical University, hoping to popularize the "Yixian Mode" to more breasts of Chinese hospitals, driving local breast cancer patients to be standardized and precise , More effectively improving their survival rate and quality of life. "I hope to benefit more patients with breast tumors," Liu Qiang said.

- END -